as of 11-06-2026 3:55pm EST
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | KANSAS CITY |
| Market Cap: | 70.2M | IPO Year: | 2021 |
| Target Price: | $21.20 | AVG Volume (30 days): | 114.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | 56.47 |
| 52 Week Low/High: | $3.16 - $11.89 | Next Earning Date: | 11-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -3.45 | Index: | N/A |
| Free Cash Flow: | -17407320.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Aug 13, 2026 · 100% conf.
1D
-8.96%
$4.54
Act: +2.00%
5D
-18.08%
$4.09
20D
-14.51%
$4.27
Transcript text not available. View on SEC.gov →
May 14, 2026
Mar 18, 2026
See how CING stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CING Cingulate Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.